```html

Bilateral Renal Agenesis – Comprehensive Medical Guide

Overview

Bilateral renal agenesis (BRA) is a rare congenital condition in which both kidneys fail to develop during fetal life. Because the kidneys are essential for producing urine and filtering waste, the absence of both kidneys leads to severe oligohydramnios (low amniotic fluid) and is almost always fatal in utero or shortly after birth.

While BRA is a condition that primarily affects fetuses, the term is also used in the context of prenatal counseling and perinatal care. The condition does not affect individuals after birth because survival is rare without immediate renal replacement therapy such as dialysis or transplantation, which are not feasible for newborns with BRA.

Prevalence – The estimated incidence worldwide is roughly 1 in 5,000 to 1 in 6,000 live births, although the true incidence may be higher because many affected pregnancies end before delivery.<sup>1</sup> BRA accounts for about 20–30% of all cases of renal agenesis and is the most severe form of the spectrum that also includes unilateral renal agenesis and renal hypoplasia.

Symptoms

Because bilateral renal agenesis prevents the formation of functional kidneys, the symptoms are usually detected prenatally by ultrasound. In the rare cases where a newborn survives for a few days, the clinical picture is dominated by the consequences of anuria (absence of urine) and severe electrolyte imbalance.

Prenatal signs

• Severe oligohydramnios: markedly reduced amniotic fluid volume, often detected after 16 weeks gestation. The low fluid leads to characteristic facial features – “potter facies” – including flattened nose, recessed chin, and low-set ears.
• Pulmonary hypoplasia: under‑development of the lungs caused by lack of amniotic fluid, which normally helps stretch the fetal lungs.
• Absent bladder on ultrasound: the fetal urinary bladder is not visualized because no urine is produced.
• Non‑visualization of kidneys: bilateral kidneys are not seen on routine obstetric sonography.

Neonatal signs (if delivery occurs)

• Absence of urine output (anuria) within the first few hours of life.
• Rapidly rising serum creatinine and blood urea nitrogen (BUN).
• Severe electrolyte disturbances, especially hyperkalemia.
• Poor feeding, lethargy, and respiratory distress due to pulmonary hypoplasia.
• Facial dysmorphology consistent with Potter sequence.

Causes and Risk Factors

The exact cause of bilateral renal agenesis is not fully understood, but most evidence points to a combination of genetic and environmental factors.

Genetic factors

• Mutations in renal development genes: variants in RET, GDNF, GDNFRα1, and EYA1 have been linked to renal agenesis in animal models and occasional human cases.
• Chromosomal abnormalities: deletions or duplications involving chromosome 22q11 (DiGeorge/velocardiofacial syndrome) or trisomy 13 can include renal agenesis as part of a broader malformation pattern.
• Familial clustering: though rare, there are reports of families with multiple members affected, suggesting autosomal recessive or X‑linked inheritance in some pedigrees.

Environmental risk factors

• Maternal exposure to certain drugs (e.g., isotretinoin, ACE inhibitors) during the first trimester has been associated with renal anomalies.
• Maternal diabetes, especially uncontrolled hyperglycemia, increases the risk of a range of congenital malformations, including renal agenesis.
• Severe maternal infections (e.g., rubella) and maternal smoking have been implicated, though data are limited.

Who is at risk?

• Pregnancies in which the mother has a known genetic syndrome linked to kidney development.
• Families with a prior child with renal agenesis or other major urogenital malformations.
• Women taking teratogenic medications or with poorly controlled chronic conditions during early pregnancy.

Diagnosis

Early detection of bilateral renal agenesis is crucial for counseling, pregnancy management, and perinatal planning.

Ultrasonography

• First‑trimester scan (11‑13 weeks): may show absent kidneys but is often too early for a definitive diagnosis.
• Second‑trimester anatomy scan (18‑22 weeks): is the gold standard. The combination of bilateral renal non‑visualization, empty bladder, and severe oligohydramnios is highly suggestive of BRA.

Fetal MRI

Used when ultrasound findings are equivocal or when detailed assessment of lung development is needed. MRI can better delineate renal tissue and pulmonary structures.

Genetic testing

• Karyotype analysis: to detect chromosomal abnormalities such as trisomy 13 or 18.
• Chromosomal microarray or exome sequencing: increasingly used when a genetic cause is suspected, especially after recurrent cases in a family.

Post‑natal assessment (if infant is delivered)

• Serum creatinine, BUN, and electrolytes within the first hours of life.
• Renal ultrasound to confirm absence of renal tissue.
• Chest X‑ray to evaluate lung volumes (often markedly reduced).

Treatment Options

Because BRA is a structural absence of both kidneys, there is no curative medical therapy. Management focuses on supportive care, parental counseling, and, in rare experimental cases, renal replacement therapy.

Pregnancy management

• Counseling: Multidisciplinary discussion with maternal‑fetal medicine specialists, neonatologists, and genetic counselors.
• Termination of pregnancy: Offered in many regions when the prognosis is uniformly incompatible with life, especially when severe pulmonary hypoplasia is present.
• Expectant management: In selected cases where parents wish to continue the pregnancy, close monitoring of amniotic fluid, fetal growth, and lung development is performed.

Neonatal care (if delivery proceeds)

• Immediate respiratory support: mechanical ventilation or CPAP due to pulmonary hypoplasia.
• Peritoneal dialysis or hemodialysis: technically possible but rarely successful because of the associated lung disease and vascular access challenges.
• Renal transplantation: Not feasible in the immediate newborn period; long‑term survival would require a donor kidney and many months to years of supportive care.
• Fluid and electrolyte management: Intravenous fluids are carefully titrated to avoid fluid overload while correcting hyperkalemia and acidosis.

Medications

• Potassium‑binding agents (e.g., sodium polystyrene sulfonate) for hyperkalemia.
• Calcium carbonate or citrate to manage metabolic acidosis.
• Diuretics are ineffective because there is no renal function.

Long‑term considerations

Given the extremely poor survival rate, most families are offered palliative care pathways focusing on comfort and dignity.

Living with Bilateral Renal Agenesis

For families who have experienced a pregnancy affected by BRA, the emotional and practical implications can be profound.

• Psychological support: Grief counseling, support groups (e.g., March of Dimes, Renal Support Network), and mental‑health services are essential.
• Genetic counseling: Discuss recurrence risk (generally low but variable) and options for future pregnancies, including pre‑implantation genetic testing (PGT) if a specific mutation is identified.
• Future pregnancy planning: Early first‑trimester ultrasound, maternal‑fetal specialist referral, and avoidance of known teratogens.
• Family bonding: Even short‑lived newborns can benefit from skin‑to‑skin contact, memory‑making, and culturally appropriate rituals.

Prevention

Because many cases are sporadic and linked to genetic development, absolute prevention is not possible. However, several measures can reduce the risk of renal agenesis associated with modifiable factors.

• Pre‑conception health: Optimize control of diabetes, hypertension, and folic acid supplementation (400 µg daily).
• Avoid teratogenic drugs: Discontinue ACE inhibitors, isotretinoin, and other known embryotoxic agents before conception.
• Quit smoking and limit alcohol: Both are associated with increased risk of fetal malformations.
• Vaccinations: Ensure immunity to rubella and varicella before pregnancy.
• Genetic screening: If there is a family history of renal anomalies, consider carrier testing or pre‑implantation genetic diagnosis (PGD) when using assisted reproductive technologies.

Complications

When BRA is diagnosed, the primary complications stem from the lack of renal function and the associated pulmonary hypoplasia.

• Pulmonary hypoplasia: leading to respiratory failure, the most common cause of death.
• Severe electrolyte imbalance: hyperkalemia causing cardiac arrhythmias.
• Acidosis: metabolic acidosis from toxin accumulation.
• Fluid overload: can exacerbate pulmonary edema.
• Psychosocial impact: grief, anxiety, and depression for parents and families.

When to Seek Emergency Care

References

1. National Organization for Rare Disorders (NORD). Bilateral Renal Agenesis. Accessed March 2024.
2. Mayo Clinic. Oligohydramnios. https://www.mayoclinic.org/diseases-conditions/oligohydramnios/symptoms-causes/syc-20352509 (accessed May 2024).
3. Centers for Disease Control and Prevention. Congenital Anomalies (Birth Defects). https://www.cdc.gov/ncbddd/birthdefects (accessed April 2024).
4. NIH National Institute of Diabetes and Digestive and Kidney Diseases. Renal Agenesis. https://www.niddk.nih.gov/health-information/kidney-disease/renal-agenesis (accessed May 2024).
5. Cleveland Clinic. Potter Sequence and Bilateral Renal Agenesis. https://my.clevelandclinic.org/health/diseases/21193-potter-sequence (accessed May 2024).
6. World Health Organization. Guidelines for Prenatal Care. WHO Publication No. 2023/68. (2023).

```